课题基金 / 基金详情

SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS

SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS
阳离子抗肿瘤剂的合成与评价
批准号:
6288049
负责人:
YUQIANG WANG
金额:
$24.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-02-01 至 2003-01-31

项目摘要

项目成果

YUQIANG WANG的其他基金

相似基金

相关文献

中文摘要
翻译
恶性细胞的电负性增强。线粒体膜
英文摘要
Malignant cells exhibit increased electronegativity. The mitochondrial membrane potential is higher in carcinoma cells than in normal epithelial cells. This may be at least partially responsible for the fact that lipophilic cationic compounds selectively accumulate in carcinoma cells. We propose to synthesize and evaluate novel cationic (+)- YW-200 prodrugs. (+)-YW-200 is a new analog of CC-1065, one of the most potent anticancer drug discovered to date. YW-200 is 1000-fold more potent than doxorubicin against different tumor cell lines in vitro and shows remarkable antitumor activity in vivo without causing myelosuppression, the dose-limiting toxicity of other CC-1065 analogs. The new cationic (+)-YW-200 prodrugs will be water-soluble, selectively taken-up by cancer cells, and thus have an improved therapeutic index. PROPOSED COMMERCIAL APPLICATION: These novel compounds can be used as anticancer drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Tumor-selective Anticancer Agents
  • 批准号:
    6739779
  • 项目类别:
  • 资助金额:
    $14.6万
  • 财政年份:
    2004
  • 负责人:
    YUQIANG WANG
  • 依托单位:
Synthesis and Evaluation of Novel Antitumor Agents
  • 批准号:
    6689646
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    YUQIANG WANG
  • 依托单位:
Novel NMDA Receptor-Binding Drugs for Ischemia/Stroke
  • 批准号:
    6550204
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2002
  • 负责人:
    YUQIANG WANG
  • 依托单位:
SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS
  • 批准号:
    6420493
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2001
  • 负责人:
    YUQIANG WANG
  • 依托单位:
海外基金